Institut National de la Sante et de la Recherche Medicale Patent applications |
Patent application number | Title | Published |
20160130346 | KIR3DL2 IS A BIOMARKER AND A THERAPEUTIC TARGET USEFUL FOR RESPECTIVELY PREVENTING AND TREATING A SUBSET OF CUTANEOUS AND NON-CUTANEOUS PERIPHERAL T-CELL LYMPHOMAS - The present invention relates to a ligand molecule that specifically binds to KTR3DL2 at the surface of KTR3DL2 expressing malignant T-cells for the treatment of lymphomas. It also relates to the in vitro use of a level of expression of KIR3DL2 is a biomarker useful for diagnosing and/or monitoring a lymphoma. | 05-12-2016 |
20160123992 | METHODS FOR PREDICTING RHEUMATOID ARTHRITIS TREATMENT RESPONSE - The invention relates to methods and means for predicting rheumatoid arthritis treatment response. | 05-05-2016 |
20160075770 | Composition with Reduced Immunogenicity - The present invention relates to a composition comprising polyclonal antibodies directed against human cells, wherein the said polyclonal antibodies are devoid of a first antigenic determinant selected in a group comprising (i) N-glycol-neuraminic acid (Neu5Gc) and (ii) α-1,3-galactose and its use as a medicament | 03-17-2016 |
20150191745 | LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA - The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo. | 07-09-2015 |
20150119745 | METHOD FOR CHARACTERISING THE PHYSIOLOGICAL STATE OF A PATIENT FROM THE ANALYSIS OF THE CEREBRAL ELECTRICAL ACTIVITY OF SAID PATIENT, AND MONITORING DEVICE APPLYING SAID METHOD - The invention relates to a method for detecting a physiological state of a patient deviating from a reference physiological state, in which, after having determined, in each of Q frequency bands, R reference matrices PR | 04-30-2015 |
20150074836 | MUTATIONS OF THE PARKIN GENE, COMPOSITIONS, METHODS AND USES - The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes. | 03-12-2015 |
20150011006 | LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA - The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo. | 01-08-2015 |
20140342364 | METHODS FOR TREATMENT OF BACTERIAL INFECTIONS - The peptidoglycan layer is a vital component of the bacterial cell wall, which comprises 4→3 and 3→3 transpeptide cross-linkages, the formation of which are catalyzed by D,D- and L,D-transpeptidases, respectively. Methods for the treatment of bacterial infections with agents that inhibit L,D-transpeptidases, either alone or in combination with D,D-transpeptidase inhibitors, are provided herein. Also provided are methods for the treatment of chronic stage tuberculosis with agents that inhibit enzyme with L,D-transpeptidase activity. | 11-20-2014 |
20140199379 | COMPOSITIONS HAVING MEANS FOR TARGETING AT LEAST ONE ANTIGEN TO DENDRITIC CELLS - A composition that can be used as a vaccine containing means for targeting at least one antigen to dendritic cells and as adjuvants a granulocyte macrophage colony stimulating factor and a CpG oligodeoxynucleotide and/or a CpG-like oligodeoxynucleotide. This composition can used to treat cancers, infectious diseases caused by bacterial, viral, fungal, parasitic or protozoan infections, allergies and/or autoimmune diseases. | 07-17-2014 |
20140045692 | NANOCAPSULATION OF ESSENTIAL OILS FOR PREVENTING OR CURING INFECTIOUS DISEASES ALONE OR WITH AN ANTIBIOTIC - A composition, an encapsulated composition and/or nanoparticles comprising at least one essential oil having a large spectrum antibacterial, antiparasitic, antifungal activity and/or a plant antipathogen, optionally at least one antibiotic and optionally a pharmaceutically acceptable carrier is disclosed. Methods for treating infectious diseases and especially bacterial, parasitic, fungal and/or plant infectious by using this composition, encapsulated composition and/or nanoparticles are also disclosed. | 02-13-2014 |
20130344033 | RECOMBINANT PROBIOTIC BACTERIA FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) AND IRRITABLE BOWEL SYNDROME (IBS) - The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof. | 12-26-2013 |
20130323759 | SPINAL MUSCULAR ATROPHY DIAGNOSTIC METHODS - The present invention relates to the discovery of the human survival motor-neuron gene or SMD gene, which is a chromosome 5-SMA (Spinal Muscular Atrophy) determining gene. The present invention further relates to the nucleotide sequence encoding the SMN gene and corresponding amino acid sequence, a vector containing the gene encoding the SMN protein or a DNA sequence corresponding to the gene and transformant strains containing the SMN gene or a DNA sequence corresponding to the gene. | 12-05-2013 |
20130316359 | METHOD FOR DETERMINING CANCER PROGNOSIS - The present invention concerns an in vitro method for determining cancer prognosis for a patient suffering from early-stage or low-grade cancer, said method comprising measuring the expression level of ERRα in a biological sample comprising cancer cells. The invention further pertains to an in vitro method for determining bone metastases prognosis for a patient suffering from bone metastases comprising measuring the expression level of ERRα. Finally, the invention pertains to in vitro methods for selecting a patient suffering from cancer, and/or from cancer-derived metastasis, suitable to be treated with a preventive/aggressive therapy. | 11-28-2013 |
20130316332 | COMBINATION OF BIOMARKERS FOR THE PROGNOSIS OF RESPONSE OR NON-RESPONSE TO AN ANTI-HCV TREATMENT - The application concerns means for predicting whether a subject infected with one or more HCVs has a high probability of responding to an anti-HCV treatment which will comprise the administration of interferon and of ribavirin or whether, in contrast, that subject has a high probability of not responding to that anti-HCV treatment. The means of the invention in particular involve assaying the levels of expression of selected genes, said selected genes being:
| 11-28-2013 |
20130251692 | METHODS OF GENERATING CORNEAL CELLS AND CELL POPULATIONS COMPRISING SAME - A method of generating a population of corneal epithelial cells is disclosed. The method comprises culturing human pluripotent stem cells in corneal fibroblast-conditioned medium on a solid surface comprising an extracellular matrix component thereby generating the population of corneal epithelial cells. Isolated cell populations and corneal tissues are also disclosed, as well as uses thereof. | 09-26-2013 |
20130143317 | METHODS OF GROWING AN EMBRYO TO A BLASTOCYTE STAGE OF DEVELOPMENT - The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to a novel human embryo co-culture system to improve human embryo growth in vitro and, consequently, increase pregnancy rates in infertile women undergoing in vitro fertilization (IVF) treatment. More particularly, the present invention relates to a method of growing an embryo to a blastocyst stage of development comprising the step of coculturing said embryo in the presence of a population of cumulus cells. | 06-06-2013 |
20120207722 | Use Of Adipose Tissue Cells For Initiating The Formation Of A Functional Vascular Network - This invention relates to the use of cells of a medullary or extra-medullary white adipose tissue, in particular of an extra-medullary stromal vascular fraction (SVF) and/or mature dedifferentiated adipocytes of any origin for initiating the formation of a functional vascularisation. | 08-16-2012 |
20120039938 | COMPOSITION COMPRISING THE POLYPROTEIN NS3/NS4 AND THE POLYPEPTIDE NS5B OF HCV, EXPRESSION VECTORS INCLUDING THE CORRESPONDING NUCLEIC SEQUENCES AND THEIR THERAPEUTIC USE - The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application. | 02-16-2012 |
20110152749 | EYE INJECTION DEVICE - An injection device for injecting a product into an eye, said device comprising an injection needle and a support on which the injection needle is fixed, said device being characterized in that it comprises a locating mark disposed in such a way that the latter can be placed in contact with a defined bearing region of the surface of the eye, before any contact of the injection needle with said surface, and can then be kept in contact with said bearing region during a stage of penetration of said injection needle through said surface of the eye. | 06-23-2011 |
20110135684 | Use of L-alpha-lysophosphatidylcholine to obtain the differentiation of monocytes in mature dendritic cells in vitro - A method for treating and/or preventing certain ailments by administering to a person in need thereof L-α-lysophosphatidylcholine as an agent for activating the immune system of the person. Also, vaccine compositions that include L-α-lysophosphatidylcholine. | 06-09-2011 |
20110027318 | NUCLEOTIDE VECTOR, COMPOSITION CONTAINING SUCH VECTOR, AND VACCINE FOR IMMUNIZATION AGAINST HEPATITIS - Nucleotide vector composition containing such vector and vaccine for immunization against hepatitis. Nucleotide vector comprising at least one gene or one complementary DNA coding for at least a portion of a virus, and a promoter providing for the expression of such gene in muscle cells. The gene may be the S gene of the hepatitis B virus. A nucleotide vector composition when administered to even chronic HBV carriers is capable of breaking T cell tolerance to the surface antigens of hepatitis B virus. A vaccine preparation containing said bare DNA is injected into the host previously treated with a substance capable of inducing a coagulating necrosis of the muscle fibers. | 02-03-2011 |
20110014159 | METHOD FOR OBTAINING CHARACTERIZED MUSCLE-DERIVED CELL POPULATIONS AND USES - A method for obtaining cell populations derived from the muscular tissue and their use for preparing cell therapy products includes culturing cells previously removed by biopsy from skeletal muscular tissues, identifying the different types of cells present at different stages of culture, selecting the culture stage on the basis of the required cell population and collecting the selected culture stage for preparing a cell therapy product. The invention also concerns cell populations derived from muscular tissue obtained by implementing the method whereof the dominant cell type is CD34+, CD15+ or CD56+ or Class 1+HLA, or comprises a doubly negative CD56−/CD15− cell type or may comprise more minority CD10+, Stro-1+ and CD 117+ cell types. | 01-20-2011 |
20100291028 | USE OF IL-18 INHIBITORS FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL VASCULAR DISEASES - The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation. | 11-18-2010 |
20100068179 | Phosphohalohydrins, Process For The Production Thereof And Use Thereof - The invention provides compounds comprising at least one phosphohalohydrin group of the formula: | 03-18-2010 |
20100008941 | COMPOSITION COMPRISING THE POLYPROTEIN NS3/NS4 AND THE POLYPEPTIDE NS5B OF HCV, EXPRESSION VECTORS INCLUDING THE CORRESPONDING NUCLEIC SEQUENCES AND THEIR THERAPEUTIC USE - The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5 | 01-14-2010 |
20090317373 | Inhibition of the Anti-FVIII Immune Response - The invention relates to a compound capable of inhibiting the endocytosis of FVIII (factor VIII) by immune system cells capable of endocytosing the antigen and to the therapeutic use of such a compound for the manufacture of a medicament for use in the treatment of hemophiliacs in order to reduce the immunogenicity of FVIII and/or increase the half-life of FVIII. | 12-24-2009 |
20090304688 | Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using Gamma Delta T Cell Activators - The present invention relates to methods and compositions for increasing the efficiency of therapeutic antibodies. More particularly, the invention relates to the use of a therapeutic antibody in combination with a γδ T cell activating compound or activated γδ T cells. thereby allowing a potentiation of γδ T cell cytotoxicity in mammalian subjects in order to enhance the efficiency of the treatment in human subjects, particularly through an increase of the depletion of targeted cells. | 12-10-2009 |
20090280523 | Method for determining the molecular composition of a target tissue or another body structure, and its diagnostic applications - The present invention relates to a sampling instrument adapted for taking a sample in situ and in vivo or taking a sample ex vivo of a target tissue or body structure, in a maximum quantity of less than 10 | 11-12-2009 |
20090247623 | DERIVATIVES OF EPIRUBICIN, THEIR MEDICINAL APPLICATION AND PHARMACEUTICALY ACCEPTABLE FORMS OF DRUGS - The present invention relates to novel derivatives of epirubicin, pharmaceutical composition comprising these derivatives, and uses of epirubicin and its derivative for treating HCV. | 10-01-2009 |
20090238791 | IL-15RALPHA SUSHI DOMAIN AS A SELECTIVE AND POTENT ENHANCER OF IL-15 ACTION THROUGH IL-15BETA/GAMMA, AND HYPERAGONIST (IL-15RALPHA SUSHI - IL-15) FUSION PROTEINS - The present invention relates to the stimulation of the IL-15R beta/gamma signalling pathway, to thereby induce and/or stimulate the activation and/or proliferation of IL-15Rbeta/gamma-positive cells, such as NK and/or T cells. Appropriate compounds include compounds comprising at least one IL-15Rbeta/gamma binding entity, directly or indirectly linked by covalence to at least one polypeptide which contains the sushi domain of the extracellular region of an IL-15Ralpha. | 09-24-2009 |
20090221692 | CB2 RECEPTORS BLOCKS ACCUMULATION OF HUMAN HEPATIC MYOFIBROBLASTS: A NOVEL ANTIFIBROGENIC PATHWAY IN THE LIVER - Methods for treating diseases of the livers mediated by CB2 receptors are described. The methods may include administering an effective amount of a cannabinoid, an agent that activates a CB2 receptor, a composition that includes a non-selective agonist of CB2 and a selective antagonist of CB1, a composition that includes an agonist of CB2 receptors, and/or a composition that includes an up-regulator of CB2 receptors to a patient who has liver fibrosis. | 09-03-2009 |
20090215679 | Disease-associated proteins - Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy subjects, antibodies which recognize this protein, and methods for diagnosing such conditions. | 08-27-2009 |
20090203648 | Modified phosphocalcic compound, injectable composition containing same - A phosphocalcic compound modified by a gem-bisphosphonic acid or one of its salts, a method for preparing same, as well as its use for preparing an injectable composition. The modified phosphocalcic compound is obtained by adding a gem-bisphosphonic acid or one of its alkali metal or alkaline earth salts to a suspension of a precursor phosphocalcic compound in ultras-pure water, while stirring the reaction medium at room temperature, then in recovering by centrifuging the formed compound. The compound is useful for making an injectable composition, for use in the treatment of bone remodeling equilibrium. | 08-13-2009 |
20090191216 | Antibody or a fragment thereof, having neutralizing activity against HIV - The invention relates to a monoclonal antibody or a fragment thereof, recognizing a peptide of sequence set forth as SEQ ID NO 7 or an analogue thereof, wherein the complementarity determining region 3 (CDR3) of its H chain variable region comprises the peptide sequence set forth as SEQ ID NO 1 or a functional analogue thereof. | 07-30-2009 |
20090093428 | Nucleotide vector, composition containing such vector, and vaccine for immunization against hepatitis - Nucleotide vector composition containing such vector and vaccine for immunization against hepatitis. Nucleotide vector comprising at least one gene or one complementary DNA coding for at least a portion of a virus, and a promoter providing for the expression of such gene in muscle cells. The gene may be the S gene of the hepatitis B virus. A nucleotide vector composition when administered to even chronic HBV carriers is capable of breaking T cell tolerance to the surface antigens of hepatitis B virus. A vaccine preparation containing said bare DNA is injected into the host previously treated with a substance capable of inducing a coagulating necrosis of the muscle fibers. | 04-09-2009 |